Stock Monitor: Navidea Biopharma Post Earnings Reporting
LONDON, UK / ACCESSWIRE / April 05, 2018 / Active-Investors.com has just released a free research report on Regeneron Pharma, Inc. (NASDAQ: REGN). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=REGN as the Company's latest news hit the wire. On April 03, 2018, the Company, which is a leading biotechnology organization that invents life-transforming medicines for people with serious diseases, along with the global pharmaceutical Company, Sanofi, declared that the European Medicines Agency (EMA) has accepted for review their Marketing Authorization Application (MAA) for Cemiplimab, used for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC), or patients with locally advanced CSCC who are not candidates for surgery. Register today and get access to over 1000 Free Research Reports by joining our site below:
Active-Investors.com is currently working on the research report for Navidea Biopharmaceuticals, Inc. (NYSE AMER: NAVB), which also belongs to the Healthcare sector as the Company Regeneron Pharma. Do not miss out and become a member today for free to access this upcoming report at:
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Regeneron Pharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
Advanced CSCC, the Deadliest Non-Melanoma Skin Cancer
CSCC is the second most common type of skin cancer worldwide. In fact, the number of newly diagnosed CSCC cases is expected to rise annually.
CSCC has a good prognosis when is diagnosed early but the cancer can prove to be very difficult to treat when it is in an advanced stage. Advanced CSCC is the deadliest non-melanoma skin cancer, and patients with advanced CSCC experience reduced quality of life due to its extreme symptoms. However, so far, there are no EMA-approved treatments for advanced CSCC.
Cemiplimab for the Treatment of CSCC
Cemiplimab is an investigational human monoclonal antibody that targets the checkpoint inhibitor programmed cell death protein-1 (PD-1).
At present, Regeneron and Sanofi are jointly developing Cemiplimab under a global collaboration agreement. Regeneron developed this drug using its proprietary VelocImmune® technology that yields optimized fully human antibodies.
Cemiplimab is currently under clinical development but no regulatory authority has fully evaluated its safety and efficacy as yet.
MAA Based on Results of Recent Trials
The marketing authorization application for Cemiplimab is based on results from recent trials - the Phase-2 pivotal, single-arm, and open label clinical trial of Cemiplimab for advanced CSCC (EMPOWER-CSCC 1), and the Phase-1 data from two advanced CSCC expansion cohorts.
Both these trials enrolled patients with metastatic CSCC and patients with locally-advanced CSCC who were not candidates for surgery. Regeneron shared top-line results from the EMPOWER-CSCC 1 trial on December 13, 2017, and presented results from the Phase-1 expansion cohort at the 2017 American Society of Clinical Oncology Annual Meeting on June 04, 2017. Now, the Company is submitting the updated results from both these clinical trials for presentation at upcoming medical congresses.
EMA to Review Application for DUPIXENT
Additionally, Regeneron and Sanofi declared on April 03, 2018, that the EMA has also accepted to review their application for DUPIXENT (dupilumab), as an add-on maintenance treatment in certain adults and adolescents (12 years of age and older) with inadequately controlled moderate-to-severe asthma.
Stock Performance Snapshot
April 04, 2018 - At Wednesday's closing bell, Regeneron Pharma's stock climbed 1.55%, ending the trading session at $337.35.
Volume traded for the day: 813.66 thousand shares.
Stock performance in the last month – up 1.03%
After yesterday's close, Regeneron Pharma's market cap was at $35.71 billion.
Price to Earnings (P/E) ratio was at 25.68.
The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 1.4% at the end of the session.
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.